Following a review of the benefit-risk ratio, syrups composed with several active substances against coughs and colds will be withdrawn from the market.
From 1 January 2020 only those containing a single active ingredient can be sold, Belgium’s Federal Agency for Medicines and Health Products (FAMHP) announced.
The following cough syrups will be withdrawn from the market: Acatar, Broncho-Pectoralis Pholcodine, Inalpin, Longbalsem, Noscaflex Expectorans and Toplexil.
The Pholco-Mereprine compound formula remains available until the end of May 2020.
The consumer organization Test-Achats had already expressed reservations several years ago about the effectiveness of these cough syrups containing multiple active substances.
The Brussels Times
